Lyell Immunopharma, Inc. — Director's Dealing 2025

Jun 11, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2025-06-09

Reporting Person: Meltz Mark A (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-06-09	Option (right to buy)	$12.47	A	100000	Acquired	2035-06-08	Common Stock (100000)	Direct

Footnotes

F1: 25% of the option shares will vest on June 9, 2026, with the remaining option shares to vest in equal monthly installments over the following thirty-six months, subject to the reporting person providing service through the applicable vesting date.